Cliff Asness’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24M Sell
375,039
-3,658
-1% -$190K 0.01% 1101
2026
Q1
$18.2M Buy
378,697
+25,635
+7% +$1.14M 0.01% 1068
2025
Q4
$14.6M Buy
353,062
+20,645
+6% +$828K 0.01% 1051
2025
Q3
$12.9M Sell
332,417
-65,815
-17% -$2.14M 0.01% 990
2025
Q2
$11M Sell
398,232
-93,529
-19% -$2.38M 0.01% 937
2025
Q1
$10.9M Buy
491,761
+294,319
+149% +$6.06M 0.01% 847
2024
Q4
$3.91M Buy
197,442
+13,273
+7% +$303K 0.01% 1211
2024
Q3
$4.6M Buy
184,169
+58,174
+46% +$1.42M 0.01% 1096
2024
Q2
$2.35M Sell
125,995
-33,328
-21% -$624K ﹤0.01% 1386
2024
Q1
$3.14M Sell
159,323
-68,722
-30% -$1.34M 0.01% 1211
2023
Q4
$4M Sell
228,045
-95,533
-30% -$1.57M 0.01% 1045
2023
Q3
$5.62M Sell
323,578
-187,444
-37% -$3.16M 0.01% 868
2023
Q2
$7.2M Buy
511,022
+103,260
+25% +$1.38M 0.02% 761
2023
Q1
$4.39M Buy
407,762
+262,747
+181% +$3.46M 0.01% 950
2022
Q4
$2.17M Buy
+145,015
New +$2.11M ﹤0.01% 1218
2021
Q1
Sell
-15,390
Closed -$272K 2232
2020
Q4
$272K Sell
15,390
-2,868
-16% -$50.4K ﹤0.01% 1999
2020
Q3
$280K Buy
18,258
+7,017
+62% +$132K ﹤0.01% 1942
2020
Q2
$286K Buy
+11,241
New +$235K ﹤0.01% 1902

Other funds holding KNSA

Cliff Asness's KNSA Position: Q2 2026 in Review

Cliff Asness reduced its Kiniksa Pharmaceuticals (KNSA) stake by 0.97% in Q2 2026, selling an estimated $190K and leaving 375,039 shares worth $24M. The position accounts for 0.01% of the portfolio, ranked #1101.

Cliff Asness first reported a position in KNSA in Q2 2020 and has held it in 18 quarters since. 265 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Cliff Asness held 375,039 shares of Kiniksa Pharmaceuticals worth $24M as of Q2 2026.
  • Cliff Asness sold 3,658 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $190K.
  • Kiniksa Pharmaceuticals made up 0.01% of Cliff Asness's portfolio in Q2 2026, its #1101 holding.
  • Cliff Asness first reported a position in Kiniksa Pharmaceuticals in Q2 2020 and has held it in 18 quarters since.
  • 265 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.